WaveMan
WaveMan · Company
AMRN · Amarin Corp Plc\Uk
> Search tickers & screens ⌘K
LIVE
← All companies

AMRN Amarin Corp Plc\uk (AMRN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000897448
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · no price filed

Amarin Corp Plc\uk insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for AMARIN CORP PLC\UK in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Berg Aaron
President and CEO
BUY
2024-08-05 SECtraded 2024-08-02
160,000
$102.4K
-15.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 19.9% of the 805,380 shares held after it.
  • No other insider bought within 30 days.
Insider activity: President and CEO Berg Aaron bought about $102.4K of AMRN on Aug 2, 2024.
Holt Patrick
President and CEO
BUY
2024-01-24 SECtraded 2024-01-22
14,426
$15.7K
-52.6%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Aug 16, 2023.
  • The trade is 4.6% of the 314,426 shares held after it.
  • No other insider bought within 30 days.
Insider activity: President and CEO Holt Patrick bought about $15.7K of AMRN on Jan 22, 2024.
Ketchum Steven B
Chief Scientific Officer
SELL
2023-12-14 SECtraded 2023-12-12
34,131
$27.0K
-28.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.0% of the 566,100 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Chief Scientific Officer Ketchum Steven B sold about $27.0K of AMRN on Dec 12, 2023, the largest insider sale at the company since 2021.
Holt Patrick
President and CEO
BUY
2023-08-16 SEC
12,700
$13.3K
-42.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.1% of the 206,933 shares held after it.
  • No other insider bought within 30 days.
Insider activity: President and CEO Holt Patrick bought about $13.3K of AMRN on Aug 16, 2023, the largest insider purchase at the company since 2022.
Holt Patrick
President and CEO
BUY
2023-08-16 SEC
25,845
$27.4K
-42.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 11.1% of the 233,778 shares held after it.
  • No other insider bought within 30 days.
Insider activity: President and CEO Holt Patrick bought about $27.4K of AMRN on Aug 16, 2023, the largest insider purchase at the company since 2022.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-6.5% year over year
below 64% of Pharma & Biotech
Margin
-18.2% net margin
more than 59% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.7% of the float short (float per yahoo 2026-10-27) · 7.3 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AMRN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.6%12M
-42%-27%-13%+1%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AMRN: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in AMRN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AMRN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Karim Mikhail
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$8.4M
$1.2M
$1.9M
-75%
-10%
2020
$17.9M
-$19.6M
$4.4M
-77%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AMRN financials

Revenue growth
-6.5%
XBRL, annual
Net margin
-18.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$186.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-14.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$15.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
LongTermDebt as filed 2020-09-30 (69 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
1.66x
TTM operating cash flow over LongTermDebt as filed 2020-09-30 (69 months older than the period end) (includes the current portion)
Return on equity
-6.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-8.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$213.6M$228.6M$306.9M$369.2M
Gross profit$120.9M$81.4M$165.5M$242.5M
Operating income-$50.2M-$91.8M-$67.6M-$105.9M
Net income-$38.8M-$87.0M-$55.0M-$105.8M
EPS (diluted)-0.09-0.20-0.15-0.26
Operating cash flow$6.7M-$31.0M$6.9M-$180.1M
Cash$134.7M$121.0M$199.3M$217.7M
SEC XBRL, fiscal years, as known on 2026-10-28

AMRN Stock Sonar score 4/7 axes

Find similar shapesCompare

AMRN ranks highest on financial health (82nd percentile) and profitability (79th), and lowest on growth (36th), among Pharma & Biotech peers.

Profitability
79
Inputs
  • Return on equity-6.0% · 78 pct, sector of 545
  • Return on assets-4.2% · 79 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-8.6% · 79 pct, sector of 576
Financial health
82
Inputs
  • Debt to equity0.02x · 71 pct, sector of 352
  • Cash flow to debt1.66x · 94 pct, sector of 371
Growth
36
Inputs
  • Revenue growth, YoY-6.5% · 36 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
59
Inputs
  • Short interest, % of float+2.7% · 68 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+10.6% · 50 pct, sector of 511
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies